Back to Search
Start Over
A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma.
- Source :
-
Cancer biotherapy [Cancer Biother] 1993 Summer; Vol. 8 (2), pp. 123-36. - Publication Year :
- 1993
-
Abstract
- Purpose: To compare 2 treatment modalities with recombinant Interleukin-2 (rIL-2) for patients with advanced Renal Cell carcinoma (RCC): continuous intravenous infusion (CIV) alone versus subcutaneous (s/c) rIL-2 + Interferon-alpha (IFN-alpha).<br />Patients and Methods: Data have been collected on 425 patients with RCC, treated CIV rIL-2 alone, (225 patients), or rIL-2 by the s/c route (200 patients). Patients receiving s/c rIL-2 also received s/c IFN-alpha both drugs being administered on an outpatient basis. Patients receiving CIV rIL-2 were treated as inpatients. Patient eligibility criteria were similar on all studies, and included patients with progressive, advanced disease, but with an ambulatory performance status.<br />Results: The overall response rate for the CIV schedules was not significantly different from the s/c regimens: 15% (95% confidence limits (CL) 10-20%) vs 20% (95%CL 14-26%) with 4% CR in both approaches. Durable responses were seen in both CIV and s/c schedules and there was no evidence of a significant difference in survival in multivariate analysis. There was however an important shift in the toxicity profile. The s/c regimens do not induce a clinically detectable capillary leak syndrome, which is the dose limiting toxicity for CIV regimens.<br />Conclusion: Although the introduction of CIV regimens of rIL-2 was a major step forward compared to high-dose bolus, because most patients could be treated in a normal oncology ward, the s/c schedule of rIL-2 + IFN-alpha offers the possibility of outpatient (home) therapy, with no evidence of a reduction in efficacy.
- Subjects :
- Adult
Aged
Carcinoma, Renal Cell mortality
Female
Humans
Infusions, Intravenous
Injections, Subcutaneous
Interferon-alpha adverse effects
Interleukin-2 adverse effects
Interleukin-2 immunology
Kidney Neoplasms mortality
Male
Middle Aged
Recombinant Proteins administration & dosage
Survival Rate
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Carcinoma, Renal Cell therapy
Interferon-alpha administration & dosage
Interleukin-2 administration & dosage
Kidney Neoplasms therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1062-8401
- Volume :
- 8
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Cancer biotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 7804353
- Full Text :
- https://doi.org/10.1089/cbr.1993.8.123